L'Oréal Dermatological Beauty Pro is a digital community empowering healthcare professionals to improve their daily practice of dermatology through cutting-edge research, science and education on skin and hair care.
EFFACLAR DUO+M
Dermatological Ingredients
[PHYLOBIOMA™] to decrease C. acnes phylotype IA1 quantity and act on the microbiome
[LHA and SALICYLIC ACID] to exfoliate without irritating
[AQUA POSAE FILIFORMIS] to rebalance the skin microbiome
[PROCERAD™] exclusive patented anti-mark ceramide to prevent the pimples from leaving a red or brown mark
[NIACINAMIDE] to soothe and reduce redness
[PIROCTONE OLAMINE] to fight microbial proliferation
[Zinc PCA] to reduce sebum secretion
[LHA and SALICYLIC ACID] to exfoliate without irritating
[AQUA POSAE FILIFORMIS] to rebalance the skin microbiome
[PROCERAD™] exclusive patented anti-mark ceramide to prevent the pimples from leaving a red or brown mark
[NIACINAMIDE] to soothe and reduce redness
[PIROCTONE OLAMINE] to fight microbial proliferation
[Zinc PCA] to reduce sebum secretion
Clinical efficacy
Anti-imperfections efficacy from 8H proven on more than 13 000 acne patients.
EFFACLAR DUO+M:
EFFACLAR DUO+M:
- -57% inflammatory lesions on day 281
- -56% retentional lesions on day 282
- Corrects and prevents marks, with -42% post-inflammatory hyperpigmentation on day 561
- 3 months anti-relapse3
115 patients, phototypes, Ill to V. 2/day. Half-face DUO(+), Half-face placebo. Lesion count at D28 & D56.
2Clinical study, 45 patients, 1/day effaclar duo(+) & effaclar foaming gel 2/day, 4 weeks.
3Clinical study, 3 months, 25 subjects with Effaclar duo(+) after BPO.
2Clinical study, 45 patients, 1/day effaclar duo(+) & effaclar foaming gel 2/day, 4 weeks.
3Clinical study, 3 months, 25 subjects with Effaclar duo(+) after BPO.
EFFACLAR clinical tests
113 clinical studies on acne
Over 13,000 patients
Over 13,000 patients